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A gene’s transcriptional output is the combined product of two inputs: diffusible factors in the cellular milieu
acting in trans, and chromatin state acting in cis. Here, we describe a strategy for dissecting the relative con-
tribution of cis versus trans mechanisms to gene regulation. Referred to as trans complementation, it entails
fusing two disparate cell types and searching for genes differentially expressed between the two genomes of
fused cells. Any differential expression can be causally attributed to cis mechanisms because the two gen-
omes of fused cells share a single homogenized milieu in trans. This assay uncovered a state of transcrip-
tional competency that we termed ‘occluded’ whereby affected genes are silenced by cis-acting
mechanisms in a manner that blocks them from responding to the trans-acting milieu of the cell.
Importantly, occluded genes in a given cell type tend to include master triggers of alternative cell fates.
Furthermore, the occluded state is maintained during cell division and is extraordinarily stable under a
wide range of physiological conditions. These results support the model that the occlusion of lineage-
inappropriate genes is a key mechanism of cell fate restriction. The identiﬁcation of occluded genes by
our assay provides a hitherto unavailable functional readout of chromatin state that is distinct from and
complementary to gene expression status.
INTRODUCTION
Multicellular life is deﬁned by the presence, within a single
organism, of a wide array of cell types bearing the same
genome but disparate physiological functions. This is typically
achieved through the progressive differentiation of multipotent
stem cells into functionally specialized cells. As a general rule,
differentiated cell types can stably maintain their phenotypic
identities despite ﬂuctuations in extracellular environment and
intracellular regulatory networks (1). How cell type identity is
maintained at the molecular level is a central but poorly under-
stood question in biology. One attractive idea is that the pheno-
typic identity of differentiated cells is maintained via the
silencing of lineage-inappropriate genes—i.e. genes promoting
alternative lineages which, if expressed aberrantly, would lead
to the manifestation of incorrect cellular phenotypes (2–5).
This idea is in line with the increasing recognition that the
transcriptional output of a gene is the combined product of two
distinct inputs. The ﬁrst is the trans-acting milieu of the cell,
deﬁned as all the diffusible factors that collectively impinge
on gene regulatory sequences to promote or repress
expression. The second is the cis-acting chromatin state of
the gene itself, deﬁned as the full complement of chromatin
marks at the locus such as DNA methylation, histone modiﬁ-
cations and the binding of chromatin remodeling factors,
which in combination determine how the locus responds to
its milieu. Numerous studies have found that particular chro-
matin marks such as DNA methylation and histone hypoacety-
lation are enriched at silent loci of the genome (6–13). In most
cases, however, the exact contribution of these chromatin
marks to the silent state cannot be teased apart from the con-
tribution of milieu. This is because it is difﬁcult to know
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quence of silencing, or to what extent is the silent status of a
gene and its associated chromatin marks reversible when cel-
lular milieu changes (9,14). As such, whether gene silencing
by chromatin-based cis mechanisms plays a key role in
restricting cell fate remains to be resolved.
Monoallelic silencing such as X inactivation and imprinting
is a clear exception to the above ambiguity. Here, it can be
unequivocally ascertained that silencing is due to cis-acting
chromatin mechanisms in a manner independent of milieu.
The hallmark of monoallelic silencing is the differential
expression of two copies of a gene—one silent and one
active—in the same cell (15–17). The active copy serves as
a positive control, attesting to the presence of a milieu that
is conducive to the expression of the gene. In this context,
the silent copy, which is bathed in the same milieu, must
have been blocked from the milieu’s action by the cis effect
of its chromatin state. Thus, at least in the case of monoallelic
silencing, the transcriptional competency of a gene can be
deﬁned as existing in either of two states. One is the ‘compe-
tent’ state whereby a gene is capable of responding to the
milieu of the cell, such that it is active if appropriate transcrip-
tion activators are present, and silent if activators are absent or
repressors are present. The other can be called the ‘occluded’
state whereby a gene is no longer capable of responding to the
cell’s milieu and remains silent even in the presence of a tran-
scriptionally conducive milieu.
It is reasonable to hypothesize that during development,
some genes might become biallelically occluded by mechan-
isms similar to monoallelic silencing, and that this process
could play an essential role in maintaining the phenotypic iden-
tities of cells. A key test of this model is the identiﬁcation of
biallelically occluded genes. However, the lack of a positive
control—the equivalent of the active copies for monoallelically
silenced genes—poses a technical challenge in ascertaining the
presence of biallelically occluded genes. This is because it is
impossible, without such a control, to deﬁnitively differentiate
whether a silent gene is in the occluded state or whether it is
competent but not expressed simply owing to the lack of a con-
ducivemilieu.Furthermore,biochemicalmodiﬁcationsofchro-
matin, which regulate gene expression in cis, are immensely
complex (for example, there are over 100 known chromatin
marks) (18), thus limiting the use of a ‘bottom up’ approach
to differentiate cis versus trans regulation.
Here, we describe the trans complementation assay, which
allows the systematic identiﬁcation of biallelically occluded
genes. The approach is to fuse two disparate cell types and
search in fused cells for genes silent in one genome but active
in the other. Similar to monoallelic silencing, the active
copies of genes serve as a positive control, with which the
occluded state of the silent copies can be ascertained.
RESULTS
Identiﬁcation of occluded genes via cell fusion
To identify occluded genes within speciﬁc cell types, we
employed a cell fusion strategy. For ease of description, one of
thetwocelltypesbeingfusedwillbereferredtoastheresponder
and the other the reprogrammer. The goal is toidentifyoccluded
genes in the responder, which are deﬁned operationally as genes
silent in the responder genome of fused cells but active in the
reprogrammer genome of the same cells (Table 1). We chose
human lung ﬁbroblasts (hereon abbreviated hLF) as the respon-
der and mouse skeletal muscle myoblasts (mSMM) as the repro-
grammer. Using cells from different species, sequence
divergence between orthologs can be exploited to distinguish
whether a transcript in fused cells is produced from the repro-
grammer genome or the responder genome.
The two cell populations were labeled by different ﬂuorescent
dyes and fused by polyethylene glycol. Dual ﬂuorescent cells,
which represent a small fraction of the total, were isolated by
ﬂuorescence-activated cell sorting (FACS) (Supplementary
Material, Fig. S1A). Microscopy conﬁrmed that FACS-isolated
cells were predominantly (.98%) fusions between hLF and
mSMM, as they contained multiple nuclei of two distinct mor-
phologies (hLF nuclei are larger and have weaker DAPI staining
relative to mSMM) (Supplementary Material, Fig. S1B). For a
subset of experiments, cells of heterotypic fusion (i.e. fusion
between hLF and mSMM) were further enriched by antibiotics
that eliminated unfused cells or cells of homotypic fusion. Of
the fused cells, .70% showed equal numbers of hLF versus
mSMM nuclei, the great majority of which possessed one hLF
and one mSMM nucleus, whereas the rest contained two hLF
and two mSMM nuclei. Less than 30% of cells showed
unequal numbers of hLF and mSMM nuclei, the majority of
which had an overrepresentation of mSMM nuclei (Supplemen-
tary Material, Fig. S1C). Fused cells were cultured for varying
periods of time to allow for the resetting of gene expression in
the new cellular milieu. Regardless of culture period and
mediumformulation,fusedcellsremainedasmultinucleatedhet-
erokaryons,indicatingthattheyhadlosttheabilitytodivideafter
fusion.Wefoundthatgeneexpressionpatternsbecamestabilized
within3 days offusion(see what follows). We therefore focused
on day 4 post-fusion for our analysis of gene expression.
To interrogate gene expression in hLF and mSMM before
and after fusion, we used human and mouse Affymetrix micro-
arrays. Although there is signiﬁcant sequence divergence
between human and mouse genomes (average 16% in coding
regions), a human transcript in fused cells may still hybridize
to orthologous probes on the mouse arrays and vice versa,
given that the arrays are not designed for species-speciﬁc
hybridization. To examine how serious a problem cross-
species hybridization might be, we hybridized cRNA from
Table 1. Expression patterns of occluded, transactivated and extinguished genes
Expression pattern in reprogrammer Expression pattern in responder Conclusion
Before fusion After fusion Before fusion After fusion
Active Active Silent Silent Gene in responder occluded
Active Active Silent Active Gene in responder transactivated and hence competent
Active Silent Silent Silent Gene in reprogrammer extinguished
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cRNA from the correct species was hybridized to the arrays,
45% of all the genes were called present. In contrast,
cRNA from the wrong species only led to 10% of the
genes being called present. This shows that the arrays have
sufﬁcient species speciﬁcity to interrogate the expression of
a considerable fraction of genes in fused cells, but it also
demonstrates the need for validation by more stringent
methods.
Four sets ofarray data were generated: hLF onhuman arrays,
mSMMonmousearrays,fusedcells onhumanarrays andfused
cells on mouse arrays. To ensure robustness of the analysis, we
ﬁrst narrowed down to a list of genes shown by the array data to
be active in mSMM but silent in hLF prior to fusion. If, in the
fused cells, these genes remain active in the mSMM genome
and silent in the hLF genome, they would be placed in a candi-
date list of occluded hLF genes.
This analysis generated a candidate list of 279 putatively
occluded hLF genes, all of which were subject to RT–PCR
validation. For each gene, we designed and conﬁrmed
mouse-speciﬁc and human-speciﬁc RT–PCR primers to
allow mouse and human gene expression in fused cells to
be interrogated independently. Consistent with previous
Affymetrix microarray studies (19), our RT–PCR analysis
showed that absence calls in the array data are much less
reliable than presence calls. As a result, a large number of
the candidate-occluded hLF genes from the array data were
shown by RT–PCR to be expressed at appreciable levels
in hLF both before and after fusion. Winnowing out these
and other false leads, 24 genes were conﬁrmed by RT–
PCR to exhibit expression patterns consistent with their
occluded status in hLF (Fig. 1A and Supplementary Material,
Table S1). Of these, nine have known muscle-related func-
tions (indicated in Fig. 1A). PCR on genomic DNA of
fused cells using human-speciﬁc primers successfully ampli-
ﬁed the hLF copies of all these genes, indicating that their
lack of expression in fused cells is not due to the absence
of hLF chromosomes (data not shown). Indeed, it is unlikely
that chromosome loss should occur in mitotically arrested
heterokaryons.
Applying the criteria in Table 1, we also obtained a
candidate list of 1040 putatively transactivated hLF genes.
Given that transactivation was not the focus of the study, we
selected only a subset of 202 genes for RT–PCR validation.
Figure 1. Identiﬁcation of occluded genes. (A) Expression analysis of the hLF–mSMM fusion by RT–PCR. Four classes of genes are shown: occluded hLF
genes, transactivated hLF genes, extinguished mSMM genes and occluded mSMM genes. For each gene, four RT–PCR results are shown: the two on the
top target the mSMM ortholog before and after fusion, whereas the two on the bottom target the hLF ortholog before and after fusion. Known muscle-related
genes are indicated by ‘þ’ above the gene name. (B) Summary of whether genes are occluded (denoted by O) or transactivated (T) in hLF, mCEF and cDF. hLF,
human lung ﬁbroblasts; mSMM, mouse skeletal muscle myoblasts; mCEF, mouse cloned embryonic ﬁbroblasts; cDF, chimpanzee dermal ﬁbroblasts.
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appreciable levels of expression in hLF both before and after
fusion. For a lot of these, RT–PCR did show increased
expression after fusion, but we did not consider them as trans-
activated genes per our stringent deﬁnition of transactivation.
This led to the identiﬁcation of 10 transactivated hLF genes, of
which 7 have known muscle-related functions (Fig. 1A and
Supplementary Material, Table S1). For three of the genes
(Ckm, Acta1 and Myl1), their transactivation is consistent
with previous reports (20,21). For transactivated genes that
showed signiﬁcantly less ampliﬁcation of the hLF transcripts
than the mSMM transcripts in fused cells (such as Myog,
Acta1 and Rap1ga1), additional sets of primers conﬁrmed
that the differences in ampliﬁcation reﬂected actual gene
expression differences between the human and mouse ortho-
logs, rather than differences in PCR efﬁciencies. In principle,
the observed differences in gene expression between human
and mouse transcripts in fused cells could be due to at least
three possibilities. First, these genes could be partially
occluded such that they turn on in response to the introduction
of a conducive milieu, but not to the full extent possible (see
Discussion). Second, the hLF cell population may be hetero-
geneous, with the genes in question being occluded in some
but not all the cells. A third possibility is that incompatibility
between mouse transcription factors made from the mSMM
genome and human cis-regulatory sequences in the hLF
genome results in only partial activation of these genes. This
possibility is addressed in greater detail later.
Our results demonstrate that, although both occluded and
transactivated genes are silent in hLF prior to fusion, they
clearly exist in two distinct states of transcriptional compe-
tency. Occluded genes do not become active even in the pre-
sence of a transcriptionally conducive milieu. In contrast,
transactivated genes exist in a competent (though inactive)
state that can turn on in response to the introduction of trans-
acting factors in the milieu.
Ad hoc RT–PCR analysis also uncovered four extinguished
mSMM genes and six occluded mSMM genes (Fig. 1A).
Extinction could result either from the introduction of tran-
scriptional repressors or from the dilution or disappearance
of transcriptional activators upon fusion (22). For extinguished
mSMM genes, it is not possible to determine whether their
orthologs in hLF are occluded or not. The presence of
occluded mSMM genes indicates that a given cell fusion
experiment can be used to identify occluded genes in both
fusion partners, even though we chose to focus only on hLF
in this study.
The identiﬁcation of occluded hLF genes was carried out in
a systematic and unbiased fashion, in the sense that all the can-
didate occluded genes based on the array data were subject to
RT–PCR validation. The ﬁnal tally of 24 occluded hLF genes
therefore likely represents a considerable fraction of all
occluded hLF genes in the context of the hLF–mSMM
fusion experiment. In contrast, the transactivated hLF genes,
extinguished mSMM genes and occluded mSMM genes
were uncovered by less systematic means.
The speciﬁcation of the myogenic lineage is controlled by
four transcription factors, Myod1, Myf5, Myog and Myf6
(23–27). Of these myogenic master triggers, Myod1 and
Myf5 are occluded in hLF, Myog is transactivated (and there-
fore competent) in hLF and Myf6 is extinguished in mSMM
(and therefore may be either occluded or competent in hLF).
Interestingly, Myod1 and Myf5 are known to be upstream of
Myog and Myf6 in driving myogenic programs, and they
also engage in positive autoregulation and positive cross-
regulation (28,29). Given such a regulatory circuit, should
Myod1 and Myf5 not undergo occlusion in non-muscle cells,
any low-level expression of these genes caused by cellular
noise is likely to get ampliﬁed through a positive feedback
loop, which in turn could trigger the erroneous manifestation
of muscle phenotype in non-muscle cells. The fact that
Myod1 and Myf5 are occluded in hLF (and in other
non-muscle cell types as shown in what follows) is therefore
consistent with the model that the occlusion of key
lineage-inappropriate genes serves to restrict cell identity
against aberrant transdifferentiation.
Temporal stability of occluded state in fused cells
Toinvestigatehowtheresettingofgeneexpressioninfusedcells
is inﬂuenced by culture time, we incubated cells for 1, 2, 3, 4, 8
or 16 days after fusion. RT–PCR was used to examine the
expression of genes listed in Figure 1A. This showed that the
resetting of gene expression occurred mostly within the ﬁrst 3
daysoffusion(datanotshown),withexpressionpatternsbecom-
ing stabilized after that. Importantly, occluded genes remained
silent regardless of post-fusion incubation time (Supplementary
Material, Fig. S2), demonstrating the temporal stability of the
occluded state in fused cells. This temporal stability is further
corroborated by experiments involving the fusion of other cell
types (see what follows).
Observed gene occlusion not due to interspecies
incompatibility
It is possible that what appears to be the occlusion of hLF
genes may actually be the result of interspecies incompatibility—
i.e. failure of mouse transcription factors produced from the
mSMM genome to recognize the corresponding human cis-
regulatory sequences in the hLF genome. To address this
issue, we fused two cell types that are both of mouse origin
but from different strains. One of the two cell types is
mSMM, which we have already used, is of C3H strain back-
ground. The other is mouse-cloned embryonic ﬁbroblasts
(mCEF) of B6 strain background. We exploited sequence
polymorphisms between the B6 and C3H mouse strains to
determine the origin of transcripts in fused cells.
Among the 24 occluded and 10 transactivated hLF genes,
11 and 3, respectively, were found to be informative in the
mCEF–mSMM fusion, meaning that they bear exonic poly-
morphisms between the two strains based on our resequencing
data, and are expressed in mSMM but not mCEF based on
RT–PCR data. For each of these genes, RT–PCR primers
were designed to ﬂank an inter-strain polymorphic site. The
relative abundance of mCEF (B6 strain) versus mSMM
(C3H strain) transcripts of the gene in mCEF–mSMM
fusion cells was then assessed by sequencing the RT–PCR
product. This analysis showed that, of the 11 informative
genes occluded in hLF, all but one are also occluded in
mCEF based on their exclusive expression from the mSMM
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Myod1 and Myf5 (Fig. 2; data also summarized in Fig. 1B).
The single exception is Chrnd, which is expressed at
roughly equal levels from both mSMM and mCEF alleles,
indicating transactivation. Of the three informative genes
transactivated in hLF, two were also found to be transactivated
in mCEF and one was occluded in mCEF (Fig. 2; also sum-
marized in Fig. 1B). Similar to the hDF–mSMM fusion
described earlier, genes found to be occluded in mCEF in
the mCEF–mSMM fusion experiment remained silent in
fused cells independent of culture time (Supplementary
Material, Fig. S3). Thus, among the informative genes, those
occluded in hLF are almost all occluded in mCEF and those
transactivated in hLF are mostly transactivated in mCEF.
These results offer strong evidence that interspecies incompat-
ibility played a negligible role in the identiﬁcation of occluded
genes in the hLF–mSMM fusion, though we cannot rule out
the possibility that incompatibility might have affected a
small number of genes. The fact that Chrnd appears occluded
in hLF but transactivated in mCEF suggests the possibility that
the observed occlusion of this gene in hLF might be an artifact
of interspecies incompatibility in the hLF–mSMM fusion.
However, we think that this is unlikely based on data pre-
sented in the following section.
Figure 2. Expression analysis of the mCEF–mSMM fusion by RT–PCR and sequencing on genes found to be occluded or transactivated in hLF. (A) RT–PCR
performed with primers common to mCEF and mSMM. It showed expression in mSMM and fused cells but not in mCEF. (B) Sequencing of RT–PCR products
from fused cells (last row of chromatograms). Eleven of the 14 genes are occluded in mCEF, as only the mSMM allele is expressed in fused cells. In contrast,
Chrnd, Myog and Myl4 are transactivated, as both mCEF and mSMM alleles are expressed. The ﬁrst two rows of chromatograms are sequences of either mSMM
or mCEF alone, showing different alleles between these two cell types. Red arrows in chromatograms indicate sites that are polymorphic between mCEF and
mSMM. mCEF, mouse cloned embryonic ﬁbroblasts; mSMM, mouse skeletal muscle myoblasts; hLF, human lung ﬁbroblasts.
Human Molecular Genetics, 2009, Vol. 18, No. 5 839Conservation of occluded state across species
Comparison between hLF and mCEF suggests that the set of
genes subject to occlusion in a given cell type—ﬁbroblasts
in this case—is relatively conserved between divergent
species. To further investigate this conservation, we fused
chimpanzee dermal ﬁbroblasts (cDF) with human skeletal
muscle myoblasts (hSMM) in order to examine whether
genes occluded in hLF are also occluded in cDF. The
human–chimpanzee genome divergence is about 1/30 of that
between human and mouse and is in fact less than the poly-
morphism levels within many species. Interspecies incompat-
ibility should therefore not be a signiﬁcant issue in this case.
Of the 24 occluded and 10 transactivated hLF genes, 12 and
8, respectively, were found to be informative in the cDF–
hSMM fusion. For these genes, RT–PCR was performed on
cDF–hSMM fusion cells using primers common to both
species but ﬂanking human–chimpanzee nucleotide substi-
tutions. Sequencing of the RT–PCR products revealed that,
of the 12 informative genes occluded in hLF, all are occluded
in cDF (Supplementary Material, Fig. S4; summarized in
Fig. 1B). The occluded cDF genes include Chrnd, which is
transactivated in mCEF, suggesting that the occluded status
of this gene in hLF is real. Of the eight informative genes
transactivated in hLF, six are transactivated in cDF, whereas
the other two are occluded in cDF (Supplementary Material,
Fig. S4; summarized in Fig. 1B).
Thus, the occluded or transactivated state of genes in hLF is
closely recapitulated in both mCEF and cDF, indicating that
the set of genes subject to occlusion in a given cell type is
strongly conserved across species. Such conservation argues
that the occlusion of lineage-inappropriate genes is a highly
regulated process with important biological functions.
Effect of DNA synthesis and nuclear merger on the
occluded state
In the mCEF–mSMM fusion experiment, we observed that
even though the majority of cells were heterokaryons immedi-
ately after fusion and FACS puriﬁcation, most cells became
mononucleated after a few days of culture. Furthermore, the
average nuclear diameter of these mononucleated cells is
40% larger than that of either mCEF or mSMM alone (Sup-
plementary Material, Fig. S5A). We suspected that this was
due to the formation of a single nucleus from the multiple
nuclei in a given fused cell (i.e. nuclear merger). The most
likely scenario that multiple nuclei of a heterokaryon could
merge is the breakdown and reassembly of the nuclear envel-
ope as the cell undergoes mitosis. For this to occur, cells in the
mCEF–mSMM fusion must be capable of DNA synthesis and
mitosis. This is consistent with the observation that the mono-
nucleated cells proliferated in number while in culture.
By monitoring the incorporation of the thymidine analog
5-bromo-20-deoxyuridine (BrdU), we conﬁrmed that the
majority of fused mCEF–mSMM cells underwent de novo
DNA synthesis a few days after fusion (Supplementary
Material, Figs S5B and C). To further conﬁrm that the
single nucleus present in each of the mononucleated cells
indeed contains both mCEF and mSMM genomes, we
labeled mCEF and mSMM DNA, prior to fusion, with the
thymidine analogs 5-chloro-20-deoxyuridine (CldU) and
5-iodo-20-deoxyuridine (IdU), respectively. Four days after
fusion and FACS puriﬁcation, cells were co-immunostained
for CldU and IdU. For the great majority of mononucleated
cells, the nuclei were found to be double-positive for both
CldU and IdU, consistent with the merger of the mCEF and
mSMM nuclei (Supplementary Material, Fig. S5D).
One complicating factor in identifying occluded genes in
fused cells that have undergone mitosis is the possibility of
chromosome loss. If some chromosomes are preferentially
lost, they would be underrepresented in fused cells and the
genes they carry could appear occluded. We addressed this
issue by performing PCR on genomic DNA of the fused
cells, amplifying across the same polymorphic sites as those
interrogated by RT–PCR. Sequencing of PCR products indi-
cated the presence of both alleles at comparable levels for
all genes investigated, which are physically scattered across
the genome (data not shown). The allele-speciﬁc expression
seen in Figure 2 is therefore not the result of chromosome
loss. These data also argue that the DNA synthesis observed
in the fused mCEF–mSMM cells is likely contributed by
the replication of both the mCEF and mSMM genomes,
because if only one of two genomes has undergone replication,
the alleles of the replicating genome should be consistently
overrepresented in the genomic PCR product over the alleles
of the non-replicating genome, which is not the case.
It is not clear why cells in the mCEF–mSMM fusion can
undergo division whereas cells in the other fusion experiments
of this study remain largely as mitotically arrested heterokar-
yons. This notwithstanding, the fact that occluded genes can
be uncovered even after heterokaryons have undergone div-
ision argues that the occluded state is robust to DNA replica-
tion, nuclear merger and changes in the cell cycle state.
Occlusion of muscle-related genes in diverse non-muscle
cell types
If the occlusion of muscle-related genes, especially Myod1 and
Myf5, indeed serves to safeguard hLF against the accidental
activation of myogenic programs, then similar sets of
muscle-related genes are likely to be occluded in other cell
types of non-myogenic lineages. To test this possibility, we
fused mSMM with non-muscle cell types of diverse lineages,
and performed RT–PCR to examine whether the 24 genes
occluded in hLF are also occluded in these other cell types.
The non-muscle cells used included human mesenchymal
stem cells (hMSC), human keratinocytes (hKe) and the
human cervical cancer cell line Hela. These cells provide a
broad representation of both stem cells and differentiated
cells, both normal cells and transformed cells and cells
derived from different germ layers.
We found that of the nine known muscle-related genes
occluded in hLF, the majority are also occluded in all these
additional non-muscle cell types, including the myogenic
master regulators Myod1 and Myf5 (Supplementary Material,
Fig. S6). Of the remaining 15 occluded hLF genes not
known to be muscle-related, most were either expressed
prior to fusion or were transactivated upon fusion in at least
one of the non-muscle cell types interrogated. These results
support the model that the occlusion of lineage-inappropriate
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contributes to the restriction of cell fate.
Stability of the occluded state under varying
physiological conditions
If the occluded state is indeed critical in safeguarding cell
identity as we have proposed, then it should be stable under
a variety of physiological conditions. To investigate this, we
subjected hLF to a variety of culture conditions mimicking
various types of physiological stress, including low nutrient,
hypoxia, hypothermia and hyperthermia. We also included
interferon-g treatment, which is known to have a dramatic
effect on the expression of many genes in a variety of cell
types including ﬁbroblasts (30). We then examined the result-
ing expression patterns of the 24 occluded genes under these
culture conditions. All of them remained silent regardless of
condition (Fig. 3A). As a control, we identiﬁed a set of 61
genes silent in hLF under the normal culture condition based
on microarray data and RT–PCR validation. We then exam-
ined their expression patterns under the alternative culture
conditions. A total of 24 of the 61 genes (39%) became
active in at least one of the conditions (Fig. 3B), which
is statistically highly distinct from the behavior of zero
Figure 3. The expression status of occluded genes versus control genes under various culture conditions. Besides the normal culture condition, ﬁve additional
conditions mimicking physiological variation were used, including low nutrient, hypoxia, hypothermia, hyperthermia and interferon-g treatment. Control genes
were selected on the basis of being silent under the normal condition. (A) Stable silencing of occluded genes in hLF under various conditions. (B) Activation of
some of the control genes in hLF under culture conditions mimicking physiological variation. Genes activated under one or more conditions are indicated by ‘ ’.
Human Molecular Genetics, 2009, Vol. 18, No. 5 841activation among the 24 occluded genes (P , 0.00007 by
Fisher’s exact test).
These results demonstrate the extraordinary stability of the
occluded state under variable physiological conditions, which
stands in stark contrast to the transcriptional lability of other
genes in the genome. Researchers have often resorted to
genome-wide gene expression patterns (i.e. the transcriptome)
as a means of deﬁning cell type identity. However, as our data
demonstrate, one cell type has the potential to display con-
siderably different gene expression patterns under different
physiological conditions, making the transcriptome too labile
to provide a consistent deﬁnition of cell type. Our results
suggest that genome-wide gene occlusion patterns (i.e. the
‘occludome’) might provide a much more consistent deﬁnition
of cell type than the physiologically labile transcriptome (see
Discussion).
DISCUSSION
Cell fusion has been used in the past to investigate gene regu-
lation, with most previous studies focusing on the transactiva-
tion and extinction of tissue-speciﬁc genes in fused cells that
indicate the presence of trans-acting transcriptional activators
or repressors (22,31–33). In this report, we demonstrate an
important utility of cell fusion as implemented in the trans
complementation assay. By fusing disparate cell types and
searching for genes differentially expressed between the two
genomes of the fused cells, the assay can dissect out the con-
tribution of cis-acting mechanisms to gene silencing apart
from the contribution of trans-acting milieu. Using this
assay, we identiﬁed a class of genes existing in what we
refer to as the occluded state, deﬁned as a state of transcrip-
tional competency whereby a gene remains silent even in
the presence of a transcriptionally conducive milieu. We
further showed that the occluded state is maintained during
cell division and is highly stable under a wide range of phys-
iological conditions.
Monoallelic silencing such as X inactivation and imprinting
clearly ﬁts the deﬁnition of the occluded state (15–17). Our
work demonstrates that biallelic occlusion also occurs as a
widespread biological phenomenon, affecting many genes in
diverse cell types. Indeed, monoallelic silencing can be
viewed as a special case of gene occlusion. It is plausible
that biallelic occlusion is the ancestral state that evolved
into existence ﬁrst, with monoallelic silencing evolving
subsequently by adopting many of the basic machineries of
biallelic occlusion but adding a mechanism for targeting one
allele (rather than both alleles) during the silencing process.
Biallelic occlusion may be key to deﬁning and restricting
the phenotypic identities of cells by stably shutting down
lineage-inappropriate genes that might otherwise become
active.
Extrapolating from our results, we argue that it may be
meaningful to take an ‘occludome’ perspective of genome
regulation—i.e. consider the genome of a cell type as compris-
ing two portions, one being the occluded genes and the other
the competent genes (Fig. 4A). Actively expressed genes in a
cell type are all competent, but silent genes can be either com-
petent or occluded. This is a different conceptual framework
for understanding genome regulation from the traditional
‘transcriptome’ perspective whereby genes are considered to
be expressed or silent (compare Fig. 4A with B).
We propose that it should be possible to systematically map
all the occluded genes in a cell type by fusing it with a wide
variety of other cell types that collectively express the entire
genome. Such an occludome map might provide a deﬁnition
of cell type that is physiologically more consistent—and mole-
cularly more fundamental—than the rather labile transcrip-
tome. By comparing occludome maps between cell types of
different lineages, between stem cells and differentiated cells
of the same lineage, between young and old cells, between
normal and pathological cells (such as cancer) and between
cells from different species, it might be possible to gain wide-
ranging insights into fundamental mechanisms of develop-
ment, aging, disease processes and evolution. Furthermore,
for a given cell type, comparisons could be made between
the occludome map and genome-wide maps of chromatin
marks such as DNA methylation and histone modiﬁcations
(34–36). Such comparisons could reveal the biochemical
underpinnings of the occluded state and, more importantly,
Figure 4. Different perspectives for understanding genome regulation.
(A) New ‘occludome’ perspective that considers the genome as consisting of
occluded genes and competent genes. (B) Traditional ‘transcriptome’ perspec-
tive that views the genome as comprisingexpressed genes and silent genes. The
occludome perspective may provide a molecularly more fundamental and
physiologically more stable deﬁnition of cell type than the transcriptome.
842 Human Molecular Genetics, 2009, Vol. 18, No. 5provide a hitherto unavailable functional readout of the
complex chromatin code superimposed on the genetic code.
For operational simplicity, the current study has taken a
binary, on/off, view of gene occlusion. However, it is plausible
that occlusion can sometimes lead to partial silencing of some
genes, in which case a gene may show a quantitative
expression difference between the two genomes of fused
cells rather than a qualitative on/off difference. In theory,
the trans complementation assay should be able to reveal
both full and partial occlusion as long as a gene displays
differential expression between the two genomes of the
fused cells (provided that confounding factors such as inter-
species incompatibility are ruled out).
The deﬁnition of the occluded state requires that a gene is
silent (or nearly silent) even in the presence of a transcription-
ally conducive milieu. It is important to note, however, that
this deﬁnition is only in reference to a particular milieu. It
may be the case that a gene occluded to one milieu might
become active in another milieu. This could happen if tran-
scription factors in the ﬁrst milieu are blocked by repressive
chromatin marks present in certain cis-regulatory sequences
of a gene, but transcription factors in the second milieu, dis-
tinct from the ﬁrst, are able to drive expression by recognizing
a different set of cis-regulatory sequences of the gene not
affected by repressive chromatin. Alternatively, factors in
the second milieu, unlike those in the ﬁrst, can recognize
their target sequences even in the presence of repressive
chromatin.
Another important possibility is that some milieus might
have the ability to ‘deocclude’ genes—i.e. erasing the chroma-
tin marks responsible for the occluded state. Such erasure
could affect individual genes or the whole genome and
could be an active process or a passive one. Reprogramming
of somatic cells by nuclear transfer into oocytes or by fusion
with embryonic stem cells (ESC) or embryonic germ cells
has demonstrated the ability of these cell types to erase
most, if not all, of the chromatin marks in somatic cells estab-
lished during development (37–43). Recent work indicates
that such ability may arise from just a few genes whose
ectopic expression can reprogram ﬁbroblasts into pluripotent,
ESC-like cells called induced pluripotent stem cells (44–
50). We hypothesize that shortly after the blastocyst stage
(where ESC is derived), cells lose their ability to deocclude
the genome, perhaps by occluding the very genes that are
responsible for genome-wide deocclusion in the ﬁrst place.
We further hypothesize that the progressive differentiation
of cells in subsequent developmental stages is accompanied
by the irreversible or nearly irreversible occlusion of an
increasing number of genes, with distinct sets of genes becom-
ing occluded in different lineages.
The occlusion of lineage-inappropriate genes could serve to
safeguard the phenotypic stability of the myriad cell types in
multicellular organisms against noise in both extracellular
environmentandintracellularregulatorynetworks.Furthermore,
that different cell types are characterized by different occlu-
domes might also explain why the same signaling pathway
often triggers the activationofdifferent sets of genes indifferent
cells—afrequentphenomenon duringthedevelopmentofmulti-
cellular organisms. The ability of the same transcription factors
toplaydifferentrolesindifferent cell typesallowsincreasedcell
type complexity inmulticellular organisms without concomitant
increases in genome size/complexity. Thus, the evolution of
some form of gene occlusion might have been a prerequisite
for the evolution of multicellularity.
The occluded state could be quite stable in order to maintain
cell identity over the entire ontology of the organism (the
germline being an exception where the occluded state is
either never fully established for most genes or is erased
during gametogenesis). For some genes, the occluded state
might be essentially irreversible in somatic cells under
normal conditions (as is the case for X-inactivated and
imprinted genes). Nevertheless, some occluded genes might
become deoccluded in certain somatic cell types by deliberate
mechanisms, which could contribute to the dedifferentiation/
transdifferentiation of cells during tissue regeneration,
especially in species capable of regenerating entire body
parts after injury (51). On rare occasions, the competent/
occluded status of genes could also change in a stochastic,
unregulated manner, which might contribute to aging and
disease processes such as cancer. The use of the trans comple-
mentation assay to systematically identify and characterize
occluded genes should therefore have wide-ranging appli-
cations in studies of health and disease.
MATERIALS AND METHODS
Cell fusion
mSMM and hLF have been described previously and are known
by their common names C2C12 and MRC-5, respectively
(21,52). C2C12 (CRL-1772), MRC-5 (CCL-171), Hela
(CCL-2), mCEF (TIB-81) and hKe (CRL-2404) were obtained
fromATCC;hMSCwerederivedasdescribed(53)andareavail-
able from Cyagen Biosciences; cDF (S006007) were obtained
from Coriell Institute for Medical Research; and hSMM
(CC-2580T25) were obtained from Cambrex. Cell culture con-
ditions followed published or vendor-supplied protocols.
Neomycin-resistant mSMM cells were generated by trans-
fection with the pEGFP-N1 plasmid (Clontech) and selection
in 800 mg/ml G418. EGFP ﬂuorescence varied within this
cell population, but was negligible compared with dye ﬂuor-
escence used for cell sorting. Puromycin-resistant hLF cells
were generated using pBabe-puro retroviral vector from
Addgene (no. 1764) (54). The vector was transfected into
ProPakA.6 packaging cells (ATCC). Forty-eight hours after
transfection, the viral supernatant was ﬁltered and added to
the cells in the presence of 8 ug/ml polybrene, and 24 h
later, cells were selected using 2 mg/ml puromycin.
One day before fusion, cells were labeled with 30 mM
CMTMR or 10 mM CMFDA Celltracker dye (Invitrogen) for
30 min at 378C in culture medium. Subsequently, the cells
were incubated in basal medium for 1 h and washed twice
with PBS. After staining, mSMM cells were kept in low-serum
medium composed of DMEM supplemented with 2% horse
serum. Cell fusion was performed with polyethylene glycol
(MW 1500) as described (55). Brieﬂy, one of the two cell popu-
lations was plated on 10 cm tissue culture dishes and the other
cell population was overlaid. After attachment, cells were
treated with warm PEG for 1 min and then washed three times
with warm basal medium. The fused cells were incubated for
Human Molecular Genetics, 2009, Vol. 18, No. 5 8432 hinlow-serummediumuntilcellsorting.Fusedcellswerepur-
iﬁed to .98% purity by FACS, with gating for dual ﬂuor-
escence. After FACS, puriﬁed fused cells were maintained in
low-serum medium until RNA extraction. The unfused
mSMM used as control in expression studies are kept in low-
serum medium for the same period as fused cells. For experi-
ments in which antibiotic-resistant cells were fused, 4–8 mg/
ml puromycin and 400–800 mg/ml G418 were added to the
medium 1 day after fusion.
Microarray analysis
Total RNA was puriﬁed from hLF, mSMM and fused cells
using TRIZOL reagent (Invitrogen) according to the
vendor’s protocol and used for microarray probe synthesis fol-
lowing standard Affymetrix protocols. Double-stranded cDNA
samples generated using GeneChip One-Cycle cDNA Syn-
thesis kit, with ﬁrst strand synthesis using oligo(dT) primers
(Affymetrix), were used to synthesize biotin-labeled cRNA
using GeneChip IVT Labeling kit (Affymetrix), and then the
labeled cRNA samples were fragmented using GeneChip
Sample Cleanup Module (Affymetrix). Hybridization, labeling
and scanning were all performed by the Protein and Nucleic
Acid (PAN) Facility at Stanford University. The labeled
cRNA sample from each cell type was hybridized to both of
mouse MG U74Av2 and human HG U133A GeneChips (Affy-
metrix) with replicates to assess gene expression and cross-
hybridization between species. Probe-level analyses of the
images from scanning of chips were performed using Affyme-
trix GeneChip Operating Software (GCOS). Similar hybridiz-
ation procedures were carried out for the hLF-most fusion.
Threshold detection P-values were set to assign ‘present’
(P , 0.05), ‘marginal’ (0.05 P   0.49) or ‘absent’ (P .
0.49) decision calls for each gene assigned by MAS 5.0 criteria
usingGCOS.Filteringgenelistsonthebasisofabsolutedecision
calls to get a candidate list of occluded genes was performed
using GeneSpring (Silicon Genetics). Occluded genes were ﬁl-
tered on the basis of the following criteria: absent calls in all
of the replicates with hLF hybridized to human chip, absent
calls in all of the replicates with fused cells hybridized to
human chip, present or marginal calls in at least one of the repli-
cates with mSMM hybridized tomousechip and present or mar-
ginal calls in at least one of the replicates with fused cells
hybridized to mouse chip. Filtering of transactivated genes
was performed by (i) comparing genes on the basis of absolute
decision calls using GeneSpring with criteria of absent calls in
all of the replicates with hLF hybridized to human chip and
present or marginal calls in at least one of the replicates with
fused cells hybridized to human chip, (ii) selecting genes
showing differential expression between the two cell types on
the basis of signal intensity after normalization by RMA using
RMAexpress (http://rmaexpress.bmbolstad.com) or (iii) com-
paring the data from the two cell types by model-based
expression index analysis using dChip (http://biosun1.harvard.
edu/complab/dchip).
RT–PCR and sequencing
RNA (up to 2 mg) was used to generate cDNA using M-MLV
reverse transcriptase and random primers (Invitrogen), or
using SuperScript III First-Strand Synthesis System with
random primers for RT–PCR (Invitrogen) following the
vendor’s protocol. Semi-quantitative PCR was carried out
with variable template concentrations and PCR cycles to
obtain linear range ampliﬁcation of each gene. For the
human–chimpanzee fusion experiment, primers were selected
by identifying non-polymorphic primer sequences ﬂanking
intron-spanning amplicons that contain at least one single-
nucleotide substitution between the two species based on
genomic sequence alignment. For the mouse–mouse fusion
experiment, amplicons containing at least one polymorphism
between the two mouse strains were identiﬁed by sequencing
randomly chosen intron-spanning amplicons. Sequences of
PCR primers and detailed conditions for RT–PCR are avail-
able upon request. All DNA sequence analysis was performed
with the ABI 3730 DNA Analyzer using the ABI BigDye Ter-
minator (Applied Biosystems).
Analysis of DNA synthesis and nuclear merger
For the analysis of nuclear merger, unfused cells were labeled
with 10 mM IdU or CldU in the media for 72 h prior to fusion,
and fused cells were stained speciﬁcally with mouse mono-
clonal anti-IdU (Becton-Dickinson, 347580; 1:500 dilution)
and rat monoclonal anti-CldU antibodies (Accurate,
OBT0030; 1:250) on the basis of published protocol (56).
These two antibodies do not cross-react when used for double-
staining IdU and CldU, but both recognize BrdU. Secondary
antibodies were Oregon Green-labeled goat anti-mouse (Invi-
trogen; 1:1000) and Cy3-labeled mouse anti-rat antibodies
(Jackson Immunoresearch; 1:300). For the analysis of DNA
synthesis, BrdU was administered at 10 mM in the media
immediately following cell fusion for 72 h, and the cells
stained with anti-BrdU antibody (Accurate, OBT0030;
1:250) at a later time point. Because the incorporation of halo-
genated nucleotides into DNA could affect gene expression,
the fusion experiment involving labeling with halogenated
nucleotides is done separately from the fusion experiment
for ascertaining the expression status of genes.
Analysis of gene expression under
physiological alterations
Cells were cultured under either the normal condition (10%
fetal calf serum at 378C) or one of the conditions mimicking
physiological alterations, including low nutrient (0.1%
serum), hypoxia (380 mM of the hypoxia mimetic deferoxa-
mine), hypothermia (338C), hyperthermia (418C) and
interferon-g treatment (100 ng/ml; Cell Sciences). Cells were
maintained under each condition for 3 days, followed by
RT–PCR analysis of selected genes as described earlier.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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